Aastrom is developing autologous stem cell products for use in regenerative medicine. Aastrom's platform manufacturing technology enables the production of patient-specific cell products with multiple tissue regenerative capabilities from a small sample of the patient's bone marrow.

Aastrom's Tissue Repair Cell (TRC) products have been used in over 325 patients, and are currently in clinical trials for cardiac, vascular and bone tissue regeneration applications, with plans to expand into the neural therapeutic area.